XEN1101 — Competitive Intelligence Brief

XEN1101 (XEN1101) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: sodium channel blocker. Area: Pain.

phase 3 sodium channel blocker Nav1.7 Pain Small molecule

Target snapshot

XEN1101 (XEN1101) — Xenon Pharmaceuticals Inc.. XEN1101 is a selective Nav1.7 sodium channel blocker.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
XEN1101 TARGET	XEN1101	Xenon Pharmaceuticals Inc.	phase 3	sodium channel blocker	Nav1.7
Journavx	SUZETRIGINE	Vertex Pharms Inc	marketed	Sodium Channel Blocker [EPC]		2025-01-01
Standard dose oxcarbazepine	Standard dose oxcarbazepine	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant; sodium channel blocker	Voltage-gated sodium channels
Medium-dose anrikefon	Medium-dose anrikefon	Peking University First Hospital	marketed	Sodium channel blocker	Nav1.5
Trileptal®	Trileptal®	Teva Pharmaceuticals USA	marketed	Anticonvulsant; sodium channel blocker	Voltage-gated sodium channels
oral suzetrigine	oral suzetrigine	University of Louisville	marketed	Selective sodium channel blocker	Voltage-gated sodium channels (Nav)
Intravenous Lidocaine infusion + Standard Anesthesia	Intravenous Lidocaine infusion + Standard Anesthesia	Instituto Mexicano del Seguro Social	marketed	Local anesthetic (sodium channel blocker)	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (sodium channel blocker class)

1. Eisai Inc. · 1 drug in this class
2. Pfizer · 1 drug in this class
3. Salvat · 1 drug in this class
4. XenoPort, Inc. · 1 drug in this class
5. Xenon Pharmaceuticals Inc. · 1 drug in this class